Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

12.62 +0.43 (+3.53%)
Streaming Delayed Price Updated: 11:00 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cullinan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Q3 2025 Earnings Beat Estimates and Announces Strategic Pipeline Refocus ↗
Cullinan Therapeutics (CGEM) beat Q3 2025 EPS estimates, announced a strategic pipeline focus, and has cash into 2029. 
Via Chartmill
Topics Earnings
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations ↗
Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented at ESMO 2025. 
Via Benzinga
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan (CGEM) Q2 R&D Jumps 68% ↗
Via The Motley Fool
News headline image
CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Reports Wider Q2 2025 Loss, Misses EPS Estimates Amid Rising R&D Costs ↗
Cullinan Therapeutics (CGEM) reported a Q2 2025 net loss of $70.1M (-$1.07/share), missing EPS estimates. Revenue was $0.0. R&D costs rose, but cash reserves remain strong at $510.9M. Stock dipped 2.7%... 
Via Chartmill
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix ↗
Cullinan Therapeutics secured global rights, excluding Greater China, to velinotamig from Genrix Bio, expanding its autoimmune pipeline with a second T cell engager. 
Via Stocktwits
News headline image
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
From Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate 
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.